1947-P: Assessing Advanced Glycation Endproducts Using a Wearable Health Monitoring Device

Introduction and Objective: Advanced glycation end-products (AGEs) are formed by the nonenzymatic glycation of proteins, lipids, and nucleic acids, and AGE accumulation is accelerated in the setting of hyperglycemia and oxidative stress. AGEs measured by skin autofluorescence have been correlated with the development of diabetes, microvascular complications, and cardiovascular disease. This study aims to validate AGE measures from the Samsung Galaxy 7 watch and to evaluate the relationship between watch AGE readings and glycemic and metabolic outcomes. Methods: In this cross-sectional study, AGEs were measured using the AGE Reader (Diagnoptics, Netherlands) and Samsung Galaxy 7 watch in adults with and without diabetes. Bioelectrical impedance analysis (BIA), skin spectrophotometry (for skin pigmentation), and HbA1c were assessed along with detailed medical history. Ten days of continuous glucose monitoring (CGM) data were collected from personal CGM or blinded Dexcom G6Pro. Results: A total of 200 participants were enrolled. Mean age (± SD) was 49 ± 19 years, 50% were female, 64.5% identified as White, 12.5% as Black, and 9% as Hispanic. Fifty participants (25%) did not have diabetes, 13 (6.5%) had prediabetes, and 137 (68.5%) had diabetes. Watch AGE was significantly correlated with AGE Reader measurement (r=0.538, 95% CI: 0.432, 0.630). On unadjusted analyses, watch AGE was associated with HbA1c (β 0.006, 95% CI 0.003, 0.010), microvascular disease (OR 1.0269, 95% CI 1.0175, 1.0376), clinical macrovascular disease (OR 1.0317, 95% CI 1.0230, 1.0414), chronic kidney disease (OR 1.0229, 95% CI 1.0098, 1.0384), and BIA % fat (β 0.060, 95% CI 0.030, 0.091). CGM results were not correlated with watch AGE (p>0.05 for all). Adjustment for skin pigmentation did not impact these associations. Conclusion: Watch AGE measurement is associated with important clinical outcomes in people with and without diabetes and may represent a helpful tool as a personal wearable health monitoring device. Disclosure A. Fahey: None. K.R. Shank: None. J.L. Douvas: None. T. Bresnahan: None. E. Greaux: None. T. Thaweethai: None. M.S. Putman: Advisory Panel; Current; Vertex Pharmaceuticals Incorporated. Research Support; Ended; Vertex Pharmaceuticals Incorporated, Dexcom, Inc. Advisory Panel; Ended; Sanofi. Board Member; Current; Anagram Therapeutics. Research Support; Ended; Samsung. Funding Samsung